The role of the stomach in the control of appetite and the secretion of satiation peptides.
It is widely accepted that gastric parameters such as gastric distention provide a direct negative feedback signal to inhibit eating; moreover, gastric and intestinal signals have been reported to synergize to promote satiation. However, there are few human data exploring the potential interaction effects of gastric and intestinal signals in the short-term control of appetite and the secretion of satiation peptides. We performed experiments in healthy subjects receiving either a rapid intragastric load or a continuous intraduodenal infusion of glucose or a mixed liquid meal. Intraduodenal infusions (3 kcal/min) were at rates comparable with the duodenal delivery of these nutrients under physiological conditions. Intraduodenal infusions of glucose elicited only weak effects on appetite and the secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). In contrast, identical amounts of glucose delivered intragastrically markedly suppressed appetite (P < 0.05) paralleled by greatly increased plasma levels of GLP-1 and PYY (≤3-fold, P < 0.05). Administration of the mixed liquid meal showed a comparable phenomenon. In contrast to GLP-1 and PYY, plasma ghrelin was suppressed to a similar degree with both intragastric and intraduodenal nutrients. Our data confirm that the stomach is an important element in the short-term control of appetite and suggest that gastric and intestinal signals interact to mediate early fullness and satiation potentially by increased GLP-1 and PYY secretions.
Dept. of Biomedicine and Div. of Gastroenterology, Univ. Hospital Basel, Basel, Switzerland. robert.steinert@unibas.ch
Robert E
RE
Steinert
Anne C
AC
Meyer-Gerspach
Christoph
C
Beglinger
D000328:Adult; D001066:Appetite / Q000502:physiology*; D001786:Blood Glucose / Q000378:metabolism; D004311:Double-Blind Method; D004386:Duodenum / Q000502:physiology; D005260:Female; D005746:Gastric Emptying / Q000502:physiology; D054439:Ghrelin / Q000097:blood; D005934:Glucagon / Q000097:blood; D052216:Glucagon-Like Peptide 1 / Q000097:blood; D005947:Glucose / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000097:blood; D007441:Intubation, Gastrointestinal; D008297:Male; D009479:Neuropeptides / Q000378:metabolism*; D019894:Peptide YY / Q000097:blood; D012527:Satiation / Q000502:physiology*; D013270:Stomach / Q000502:physiology*; D055815:Young Adult
D001786:Blood Glucose; D054439:Ghrelin; D007328:Insulin; D009479:Neuropeptides; D019894:Peptide YY; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D005947:Glucose